Synthetic polymers for sustained metabolic support and nutrient release
Innovative synthetic polymers designed for controlled release of metabolites, enhancing metabolic support and endurance. Ideal for applications in sports nutrition, emergency nutrition, and regenerative medicine, with proven IP and scalable production.
Overview
Axilea LLC introduces synthetic polymers engineered to provide sustained release of essential metabolites, supporting cellular energy production over extended periods. Developed through patented technology by Dr. Abhinav Acharya, these polymers are designed for applications in metabolic support, endurance supplementation, emergency nutrition, and regenerative medicine. By gradually liberating small bioenergetic molecules in the gastrointestinal tract, these polymers offer enhanced oral bioavailability and optimized release profiles compared to free metabolites.
Technical specifications
The synthetic polymers are crafted from glycolytic intermediates, succinate, and α‑ketoglutarate to enable controlled hydrolysis. Key features include:
- Tunable release kinetics: Modulated polymer degradation rates allow for personalized dosing and sustained metabolite levels.
- Improved bioavailability: The polymeric backbone enhances the stability and absorption of metabolites.
- Biodegradable materials: Ensures safe metabolism and regulatory compliance, while permitting mechanical and chemical stability.
These polymers are suitable for integration into various nutritional products, offering a competitive advantage in the food, sports, and clinical nutrition markets.
Technology readiness level
Currently at TRL 4, this technology is in the validation stage with pilot manufacturing capabilities. Immunometabolix, LLC, aims to commercialize these polymers through B2B co-development and fee-for-service models, providing proprietary chemistry and controlled-release formulations to industry partners.
About Axilea LLC
Axilea LLC, which operates as ImmunoMetabolix, is a clinical-stage biotechnology company that utilizes a proprietary engineering approach to develop metabolically-fit immunotherapies. The company focuses on addressing cancer, autoimmune, and inflammatory diseases where existing treatments may be ineffective, costly, or cause significant side effects. By targeting metabolic dysfunctions that can impair the immune system, their core technology, the iMET platform, is designed to generate more potent T-cells capable of specifically killing cancer cells or inhibiting inflammatory processes.
The company's work aims to provide enhanced therapeutic efficacy and patient safety for those suffering from complex immune-related disorders. Originally spun out of research at Arizona State University, the organization works to translate advancements in cell metabolism into actionable healthcare solutions. By focusing on the metabolic fitness of immune cells, the company seeks to offer patients improved outcomes and better quality of life through novel, patient-centric clinical interventions.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.